XTRA:ACTChemicals
AlzChem Group (XTRA:ACT) Margin Improvement To 11% Tests Bullish Growth Narratives
AlzChem Group (XTRA:ACT) has opened 2026 with fresh numbers, coming off Q4 2025 revenue of €136.15 million and net income of €16.739 million, which translated into basic EPS of €1.66. Over recent quarters, the company has seen revenue move from €137.24 million in Q4 2024 to a range between €141.07 million and €151.07 million through 2025, while quarterly EPS tracked between €1.21 and €1.66, giving investors a consistent read on both the top and bottom line. With trailing net profit margins at...